AstraZeneca Discontinues Phase 3 Lung Cancer Trial for Volrustomig Combination
MT Newswires Live
Aug 17
AstraZeneca (AZN) is stopping a phase 3 trial evaluating volrustomig in combination with chemotherapy for patients with metastatic non-small cell lung cancer, the company said Monday.
An independent data monitoring committee recommended halting the trial after finding the combination was unlikely to meet its primary survival goals, the company said.
The treatment showed a safety profile consistent with existing data without any new safety signals, AstraZeneca said.
The other phase 3 studies testing volrustomig in cervical cancer, head and neck cancer, and mesothelioma will proceed as planned, it said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.